Trials / Approved For Marketing
Approved For MarketingNCT00649545
Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis
A Multi-Center Study of the Safety and Efficacy of Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Active Rheumatoid Arthritis
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The primary objective of this study is to assess the safety (by collecting adverse events and serious adverse events) of adalimumab administered every other week to patients with moderately to severly active rheumatoid arthritis who have failed prior disease-modifying anti-rheumatic drugs (DMARDs).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | adalimumab | 40 mg every other week |
Timeline
- First posted
- 2008-04-01
- Last updated
- 2008-04-01
Source: ClinicalTrials.gov record NCT00649545. Inclusion in this directory is not an endorsement.